GET DAILY SIGNALSHaemonetics (HAE) vs Sensus Healthcare (SRTS): Weighing Scale and Momentum Against Catalyst Potential
Key Takeaways
- Haemonetics (HAE) has shown strong relative momentum in recent months, supported by a plasma-collection supply agreement expansion with CSL Plasma and a series of regulatory approvals.
- Sensus Healthcare (SRTS) is a much smaller, earlier-stage medical device company whose shares have been pressured by sharply lower revenue and wider losses in recent quarters.
- HAE offers a larger scale, more diversified revenue base, and improving profitability, while SRTS carries a higher-risk, catalyst-driven profile tied to reimbursement-code adoption and unit sales.
- Tickeron AI Verdict: Based on trend consistency, stability, and recent catalysts, Tickeron's AI would currently favor HAE over SRTS.
- For additional coverage of these names, explore HAE Major News and HAE Today's Price Move, along with SRTS Major News and SRTS Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Setting the Stage for This Comparison
Investors evaluating healthcare names often weigh the stability of an established medical technology franchise against the upside potential of a smaller, catalyst-driven device company. This stock comparison examines Haemonetics Corporation (HAE), a global leader in blood and plasma collection technology, against Sensus Healthcare (SRTS), a developer of superficial radiation therapy (SRT) devices for non-melanoma skin cancer. Although both operate in medical devices, their scale, growth profiles, and risk characteristics differ markedly. The comparison is most relevant to traders and investors assessing relative performance, market positioning, and how momentum and fundamentals interact in the current environment.
Haemonetics (HAE) – Established Player with Positive Momentum
Haemonetics (HAE) develops blood and plasma collection, processing, and hospital patient-care solutions, with its Plasma and Blood Management Technologies businesses serving as core growth platforms. Recent market activity has been notably positive, with the shares advancing strongly over the past several months and reaching new 52-week highs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Two developments have shaped sentiment. First, CSL Plasma announced plans to complete deployment of Haemonetics' NexSys PCS devices and disposables across all existing U.S. plasma collection centers by the end of 2027, a meaningful expansion of a previously announced, non-exclusive supply agreement. Second, the company has received U.S. Food and Drug Administration (FDA) clearance for products including the Persona PLUS plasma technology and the PerQseal Elite vascular closure system. In its latest reported quarter, revenue rose while adjusted gross margin expanded for the full fiscal year, even as the Interventional Technologies segment remained a soft spot.
Sensus Healthcare (SRTS) – Smaller Scale, Catalyst Focus
Sensus Healthcare (SRTS) manufactures and sells superficial radiation therapy systems, including the SRT-100 portfolio, which offer a non-invasive alternative to surgery for treating non-melanoma skin cancers and keloids. The company is far smaller, with a market capitalization measured in the tens of millions of dollars, and its stock has traded near the lower end of its 52-week range in recent weeks.
Recent performance has been pressured by weak financial results. In its most recent reported quarter, revenue declined sharply year over year, reflecting the delayed recognition of several unit sales tied to third-party financing approvals, while the company posted a wider net loss. Positively, dedicated Current Procedural Terminology (CPT) reimbursement codes for superficial radiotherapy took effect in early 2026, which management views as a catalyst for adoption. Analysts have maintained buy ratings, but several lowered their price targets following the quarterly results, reflecting a recovery narrative that remains unproven.
Side-by-Side Analysis
The two companies sit at opposite ends of the healthcare-device spectrum. Haemonetics benefits from scale, a diversified portfolio across plasma, blood center, and hospital segments, and improving cash generation, giving it a more durable earnings base. Its primary risks include concentration around major plasma customers and continued softness in interventional technologies. Sensus Healthcare, by contrast, is a growth-oriented story dependent on reimbursement-code adoption, financing availability, and unit-selling momentum. Its risk profile is higher, with negative earnings and revenue volatility, though its small size and analyst price targets imply substantial potential upside if catalysts materialize. In terms of market positioning, HAE reflects established momentum and profitability, while SRTS represents a higher-risk, higher-variance opportunity.
AI-Assisted Take on the Pair
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor Haemonetics (HAE) in the current environment. The stock combines sustained positive price momentum, expanding profitability, and concrete catalysts such as the CSL Plasma rollout and recent FDA clearances. Sensus Healthcare offers a compelling but less established catalyst path, with recent financial weakness and higher volatility. Accordingly, the AI verdict tilts toward HAE on a risk-adjusted, trend-based basis, while acknowledging that SRTS retains meaningful upside potential should its reimbursement and sales catalysts accelerate.
Leveraging AI Tools in My Research Process
When I want to dig deeper into relative strength or pattern recognition across names like these, I turn to Tickeron’s AI Pattern Search Engine. It provides a quick way to scan for recurring formations and trend signals that complement traditional fundamental work, helping me refine my view on momentum versus risk without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for HAE shows an upward move is likely
HAE's Aroon Indicator triggered a bullish signal on October 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 164 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 65 cases where HAE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on HAE as a result. In 52 of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +1.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 234 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for HAE moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 30 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Moving Average Convergence Divergence Histogram (MACD) for HAE turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 24 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
HAE broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.530) is normal, around the industry mean (4.204). P/E Ratio (57.760) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of blood processing systems
Industry MedicalNursingServices
Advertisement